This study is in progress, not accepting new patients

Ahmed Glaucoma Valve Surgery With Mitomycin-C

a study on Glaucoma

Summary

Eligibility
for people ages 18-85 (full criteria)
Healthy Volunteers
healthy people welcome
Location
at San Francisco, California and other locations
Dates
study started
estimated completion
Principal Investigator
Ying Han, MD, PhD
Photo of Ying Han
Ying Han

Description

Summary

This study will determine the effectiveness of Mitomycin-C use in the glaucoma surgery Ahmed valve implantation. Approximately 100 patients will be enrolled, with half receiving the Mitomycin-C treatment and the other half receiving placebo treatment.

Details

Glaucoma is a leading cause irreversible blindness worldwide. Glaucoma valve surgeries such as Ahmed valve implantation, which are conventional surgeries performed to control intraocular pressure in eyes, are sometimes associated with complications due to fibrosis. Mitomycin-C is a commonly used antifibrotic agent used in glaucoma surgeries. This study will evaluate the effectiveness of Mitomycin-C injections intraoperatively and postoperatively.

Keywords

Glaucoma Primary Open Angle Glaucoma Secondary Glaucoma Neovascular Glaucoma Glaucoma, Open-Angle Glaucoma, Neovascular Mitomycins Mitomycin Mitomycin-C Balanced Salt Solution Balanced Salt Solution (BSS)

Eligibility

You can join if…

Open to people ages 18-85

  • Inadequately controlled glaucoma on maximum tolerated medical therapy with intraocular pressure (IOP) greater than or equal to 18 mm Hg. Ahmed Glaucoma Valve (AGV) implantation as the planned surgical procedure. For patients in whom 2 eyes are eligible for enrollment, only the first eligible eye to be implanted is enrolled.

You CAN'T join if...

  • Unwilling or unable to give consent, unwilling to accept randomization, or unable to return for scheduled protocol visits.
  • Pregnant or nursing women.
  • Previous cyclodestruction or glaucoma drainage device (GDD) surgery.
  • Patients with nanophthalmos.
  • Patients with Sturge-Weber syndrome or other conditions associated with elevated episcleral venous pressure.
  • No light perception vision.
  • VA <20/200 in non-study eye.
  • Need for glaucoma surgery combined with other ocular procedures (i.e. cataract extraction, penetrating keratoplasty, or retinal surgery) or anticipated need for additional ocular surgery.
  • Previous scleral buckling procedure or silicone oil present. Uveitic glaucoma.

Locations

  • University of California, San Francisco
    San Francisco California 94121 United States
  • Asociación para Evitar la Ceguera en México (APEC)
    Mexico City Mexico

Lead Scientist at UCSF

  • Ying Han, MD, PhD
    Professor, Ophthalmology. Authored (or co-authored) 39 research publications.

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Francisco
ID
NCT02805257
Phase
Phase 2
Study Type
Interventional
Last Updated